Nancy G Cocozza
CIK 1232953 · Former Executive VP · last filed 2026-05-22
Nancy G Cocozza is a Former Executive VP who has filed 13 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for PRVA, was dated May 22, 2026. Current disclosed insider exposure totals $970.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PRVA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
STE 400
WILMINGTON, DE 19808
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRVA | Director | 42,814 | $22.67 | $970.6K | $0 | 5 | 2026-05-22 |
| Aspira Women's Health Inc. (AWH) Delisted | Director | 8,575 | $0.08 | $703 | $0 | 1 | 2021-03-23 |
| Aspira Women's Health Inc. (VRML) Delisted | Director | 129,506 | — | — | $0 | 4 | 2020-03-23 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-22 | PRVA | Grant (A) | +8,463 | $0 | EDGAR |
| 2025-05-23 | PRVA | Grant (A) | +8,396 | $0 | EDGAR |
| 2024-05-23 | PRVA | Grant (A) | +11,124 | $0 | EDGAR |
| 2023-07-05 | PRVA | Grant (A) | +7,758 | $0 | EDGAR |
| 2022-04-05 | PRVA | Grant (A) | +7,073 | $0 | EDGAR |
| 2021-03-23 | Aspira Women's Health Inc. (AWH) Delisted | Grant (A) | +15,680 | $0 | EDGAR |
| 2020-03-23 | Aspira Women's Health Inc. (VRML) Delisted | Grant (A) | +66,218 | $0 | EDGAR |
| 2020-03-23 | Aspira Women's Health Inc. (VRML) Delisted | Grant (A) | +66,218 | $0 | EDGAR |
| 2019-03-28 | Aspira Women's Health Inc. (VRML) Delisted | Grant (A) | +35,417 | $0 | EDGAR |
| 2018-08-21 | Aspira Women's Health Inc. (VRML) Delisted | Grant (A) | +27,871 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.